Latin America, Middle East & Africa Cephalosporin Drugs Market (2019-2025)
The Latin America, Middle East and Africa Cephalosporin Drugs Market would witness market growth of 4.37% CAGR during the forecast period (2019–2025).
Antibiotics perform best when a body has a steady level of medication. This is achieved by administering the medicine all day and night at uniformly spaced intervals. The dosage is based on the condition and treatment reaction of a patient. The continued use of this medication until the recommended period is complete is usually suggested, even if the symptoms vanish after a couple of days. Stopping the medication too soon may allow bacteria to continue to develop, leading to an infection recurrence. It is further important to check the item for particles or discoloration visually before use.
Growth in population incidence with pneumonia, tonsillitis, bronchitis, and gonorrhea drives market growth. Over the previous centuries, there are over 50 Cephalosporin Drugs authorized, and nearly half of them are for antibacterial activity. Nevertheless, fresh Cephalosporin Drugss (categorized as the fifth generation) used to treat severe gram-negative bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), have lately been approved.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
Antibiotics perform best when a body has a steady level of medication. This is achieved by administering the medicine all day and night at uniformly spaced intervals. The dosage is based on the condition and treatment reaction of a patient. The continued use of this medication until the recommended period is complete is usually suggested, even if the symptoms vanish after a couple of days. Stopping the medication too soon may allow bacteria to continue to develop, leading to an infection recurrence. It is further important to check the item for particles or discoloration visually before use.
Growth in population incidence with pneumonia, tonsillitis, bronchitis, and gonorrhea drives market growth. Over the previous centuries, there are over 50 Cephalosporin Drugs authorized, and nearly half of them are for antibacterial activity. Nevertheless, fresh Cephalosporin Drugss (categorized as the fifth generation) used to treat severe gram-negative bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), have lately been approved.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
- First-Generation Cephalosporin
- Second-Generation Cephalosporin
- Third-Generation Cephalosporin
- Fourth-Generation Cephalosporin
- Fifth-Generation Cephalosporin
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Sexually Transmitted Infection
- Others
- Injections
- Oral Drugs
- Branded
- Generic
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- ABBOTT Laboratories
- Teva Pharmaceuticals Industries Ltd.
- Johnson and Johnson
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Merck & Co., Inc.
- Bayer AG
- Baxter International, Inc.
- BRISTOL-MYERS SQUIBB COMPANY
- Novartis AG
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cephalosporin Drugs Market, by Generation
1.4.2 LAMEA Cephalosporin Drugs Market, by Application
1.4.3 LAMEA Cephalosporin Drugs Market, by Route of Administration
1.4.4 LAMEA Cephalosporin Drugs Market, by Type
1.4.5 LAMEA Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION
3.1 LAMEA First-Generation Cephalosporin Drugs Market by Country
3.2 LAMEA Second-Generation Cephalosporin Drugs Market by Country
3.3 LAMEA Third-Generation Cephalosporin Drugs Market by Country
3.4 LAMEA Fourth-Generation Cephalosporin Drugs Market by Country
3.5 LAMEA Fifth-Generation Cephalosporin Drugs Market by Country
CHAPTER 4. LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION
4.1 LAMEA Respiratory Tract Infection Market by Country
4.2 LAMEA Skin Infection Market by Country
4.3 LAMEA Ear Infection Market by Country
4.4 LAMEA Sexually Transmitted Infection Market by Country
4.5 LAMEA Others Market by Country
CHAPTER 5. LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
5.1 LAMEA Injections Market by Country
5.2 LAMEA Oral Drugs Market by Country
CHAPTER 6. LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE
6.1 LAMEA Branded Market by Country
6.2 LAMEA Generic Market by Country
CHAPTER 7. LAMEA CEPHALOSPORIN DRUGS MARKET BY COUNTRY
7.1 Brazil Cephalosporin Drugs Market
7.1.1 Brazil Cephalosporin Drugs Market by Generation
7.1.2 Brazil Cephalosporin Drugs Market by Application
7.1.3 Brazil Cephalosporin Drugs Market by Route of Administration
7.1.4 Brazil Cephalosporin Drugs Market by Type
7.2 Argentina Cephalosporin Drugs Market
7.2.1 Argentina Cephalosporin Drugs Market by Generation
7.2.2 Argentina Cephalosporin Drugs Market by Application
7.2.3 Argentina Cephalosporin Drugs Market by Route of Administration
7.2.4 Argentina Cephalosporin Drugs Market by Type
7.3 UAE Cephalosporin Drugs Market
7.3.1 UAE Cephalosporin Drugs Market by Generation
7.3.2 UAE Cephalosporin Drugs Market by Application
7.3.3 UAE Cephalosporin Drugs Market by Route of Administration
7.3.4 UAE Cephalosporin Drugs Market by Type
7.4 Saudi Arabia Cephalosporin Drugs Market
7.4.1 Saudi Arabia Cephalosporin Drugs Market by Generation
7.4.2 Saudi Arabia Cephalosporin Drugs Market by Application
7.4.3 Saudi Arabia Cephalosporin Drugs Market by Route of Administration
7.4.4 Saudi Arabia Cephalosporin Drugs Market by Type
7.5 South Africa Cephalosporin Drugs Market
7.5.1 South Africa Cephalosporin Drugs Market by Generation
7.5.2 South Africa Cephalosporin Drugs Market by Application
7.5.3 South Africa Cephalosporin Drugs Market by Route of Administration
7.5.4 South Africa Cephalosporin Drugs Market by Type
7.6 Nigeria Cephalosporin Drugs Market
7.6.1 Nigeria Cephalosporin Drugs Market by Generation
7.6.2 Nigeria Cephalosporin Drugs Market by Application
7.6.3 Nigeria Cephalosporin Drugs Market by Route of Administration
7.6.4 Nigeria Cephalosporin Drugs Market by Type
7.7 Rest of LAMEA Cephalosporin Drugs Market
7.7.1 Rest of LAMEA Cephalosporin Drugs Market by Generation
7.7.2 Rest of LAMEA Cephalosporin Drugs Market by Application
7.7.3 Rest of LAMEA Cephalosporin Drugs Market by Route of Administration
7.7.4 Rest of LAMEA Cephalosporin Drugs Market by Type
CHAPTER 8. COMPANY PROFILES
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cephalosporin Drugs Market, by Generation
1.4.2 LAMEA Cephalosporin Drugs Market, by Application
1.4.3 LAMEA Cephalosporin Drugs Market, by Route of Administration
1.4.4 LAMEA Cephalosporin Drugs Market, by Type
1.4.5 LAMEA Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION
3.1 LAMEA First-Generation Cephalosporin Drugs Market by Country
3.2 LAMEA Second-Generation Cephalosporin Drugs Market by Country
3.3 LAMEA Third-Generation Cephalosporin Drugs Market by Country
3.4 LAMEA Fourth-Generation Cephalosporin Drugs Market by Country
3.5 LAMEA Fifth-Generation Cephalosporin Drugs Market by Country
CHAPTER 4. LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION
4.1 LAMEA Respiratory Tract Infection Market by Country
4.2 LAMEA Skin Infection Market by Country
4.3 LAMEA Ear Infection Market by Country
4.4 LAMEA Sexually Transmitted Infection Market by Country
4.5 LAMEA Others Market by Country
CHAPTER 5. LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
5.1 LAMEA Injections Market by Country
5.2 LAMEA Oral Drugs Market by Country
CHAPTER 6. LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE
6.1 LAMEA Branded Market by Country
6.2 LAMEA Generic Market by Country
CHAPTER 7. LAMEA CEPHALOSPORIN DRUGS MARKET BY COUNTRY
7.1 Brazil Cephalosporin Drugs Market
7.1.1 Brazil Cephalosporin Drugs Market by Generation
7.1.2 Brazil Cephalosporin Drugs Market by Application
7.1.3 Brazil Cephalosporin Drugs Market by Route of Administration
7.1.4 Brazil Cephalosporin Drugs Market by Type
7.2 Argentina Cephalosporin Drugs Market
7.2.1 Argentina Cephalosporin Drugs Market by Generation
7.2.2 Argentina Cephalosporin Drugs Market by Application
7.2.3 Argentina Cephalosporin Drugs Market by Route of Administration
7.2.4 Argentina Cephalosporin Drugs Market by Type
7.3 UAE Cephalosporin Drugs Market
7.3.1 UAE Cephalosporin Drugs Market by Generation
7.3.2 UAE Cephalosporin Drugs Market by Application
7.3.3 UAE Cephalosporin Drugs Market by Route of Administration
7.3.4 UAE Cephalosporin Drugs Market by Type
7.4 Saudi Arabia Cephalosporin Drugs Market
7.4.1 Saudi Arabia Cephalosporin Drugs Market by Generation
7.4.2 Saudi Arabia Cephalosporin Drugs Market by Application
7.4.3 Saudi Arabia Cephalosporin Drugs Market by Route of Administration
7.4.4 Saudi Arabia Cephalosporin Drugs Market by Type
7.5 South Africa Cephalosporin Drugs Market
7.5.1 South Africa Cephalosporin Drugs Market by Generation
7.5.2 South Africa Cephalosporin Drugs Market by Application
7.5.3 South Africa Cephalosporin Drugs Market by Route of Administration
7.5.4 South Africa Cephalosporin Drugs Market by Type
7.6 Nigeria Cephalosporin Drugs Market
7.6.1 Nigeria Cephalosporin Drugs Market by Generation
7.6.2 Nigeria Cephalosporin Drugs Market by Application
7.6.3 Nigeria Cephalosporin Drugs Market by Route of Administration
7.6.4 Nigeria Cephalosporin Drugs Market by Type
7.7 Rest of LAMEA Cephalosporin Drugs Market
7.7.1 Rest of LAMEA Cephalosporin Drugs Market by Generation
7.7.2 Rest of LAMEA Cephalosporin Drugs Market by Application
7.7.3 Rest of LAMEA Cephalosporin Drugs Market by Route of Administration
7.7.4 Rest of LAMEA Cephalosporin Drugs Market by Type
CHAPTER 8. COMPANY PROFILES
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:
LIST OF TABLES
TABLE 1 LAMEA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 2 LAMEA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 3 LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 4 LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 5 LAMEA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 LAMEA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 LAMEA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 LAMEA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 LAMEA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 LAMEA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 LAMEA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 LAMEA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 LAMEA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 LAMEA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 16 LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 17 LAMEA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 LAMEA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 LAMEA SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 LAMEA SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 LAMEA EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 LAMEA EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 LAMEA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 LAMEA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 28 LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 29 LAMEA INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 LAMEA INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 LAMEA ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 LAMEA ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 34 LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 35 LAMEA BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 LAMEA BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 LAMEA GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 LAMEA GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 LAMEA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 LAMEA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 BRAZIL CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 42 BRAZIL CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 43 BRAZIL CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 44 BRAZIL CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 45 BRAZIL CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 46 BRAZIL CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 47 BRAZIL CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 48 BRAZIL CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 49 BRAZIL CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 50 BRAZIL CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 51 ARGENTINA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 52 ARGENTINA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 53 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 54 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 55 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 58 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 59 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 60 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 61 UAE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 62 UAE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 63 UAE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 64 UAE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 65 UAE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 66 UAE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 67 UAE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 68 UAE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 69 UAE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 70 UAE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 71 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 72 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 73 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 74 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 75 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 76 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 77 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 78 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 79 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 80 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 81 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 82 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 83 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 84 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 85 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 86 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 87 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 88 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 89 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 90 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 91 NIGERIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 92 NIGERIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 93 NIGERIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 94 NIGERIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 95 NIGERIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 96 NIGERIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 97 NIGERIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 98 NIGERIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 99 NIGERIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 100 NIGERIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 101 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 102 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 103 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 104 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 105 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 106 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 107 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 108 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 109 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 110 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 111 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 112 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 113 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 114 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 115 KEY INFORMATION – PFIZER, INC.
TABLE 116 KEY INFORMATION – MERCK & CO., INC.
TABLE 117 KEY INFORMATION – BAYER AG
TABLE 118 KEY INFORMATION – BAXTER INTERNATIONAL, INC.
TABLE 119 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY
TABLE 120 KEY INFORMATION – NOVARTIS AG
TABLE 1 LAMEA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 2 LAMEA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 3 LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 4 LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 5 LAMEA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 LAMEA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 LAMEA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 LAMEA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 LAMEA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 LAMEA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 LAMEA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 LAMEA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 LAMEA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 LAMEA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 16 LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 17 LAMEA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 LAMEA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 LAMEA SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 LAMEA SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 LAMEA EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 LAMEA EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 LAMEA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 LAMEA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 28 LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 29 LAMEA INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 LAMEA INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 LAMEA ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 LAMEA ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 34 LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 35 LAMEA BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 LAMEA BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 LAMEA GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 LAMEA GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 LAMEA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 LAMEA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 BRAZIL CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 42 BRAZIL CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 43 BRAZIL CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 44 BRAZIL CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 45 BRAZIL CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 46 BRAZIL CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 47 BRAZIL CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 48 BRAZIL CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 49 BRAZIL CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 50 BRAZIL CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 51 ARGENTINA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 52 ARGENTINA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 53 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 54 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 55 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 58 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 59 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 60 ARGENTINA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 61 UAE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 62 UAE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 63 UAE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 64 UAE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 65 UAE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 66 UAE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 67 UAE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 68 UAE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 69 UAE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 70 UAE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 71 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 72 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 73 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 74 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 75 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 76 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 77 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 78 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 79 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 80 SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 81 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 82 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 83 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 84 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 85 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 86 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 87 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 88 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 89 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 90 SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 91 NIGERIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 92 NIGERIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 93 NIGERIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 94 NIGERIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 95 NIGERIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 96 NIGERIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 97 NIGERIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 98 NIGERIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 99 NIGERIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 100 NIGERIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 101 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 102 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 103 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 104 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 105 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 106 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 107 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 108 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 109 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 110 REST OF LAMEA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 111 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 112 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 113 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 114 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 115 KEY INFORMATION – PFIZER, INC.
TABLE 116 KEY INFORMATION – MERCK & CO., INC.
TABLE 117 KEY INFORMATION – BAYER AG
TABLE 118 KEY INFORMATION – BAXTER INTERNATIONAL, INC.
TABLE 119 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY
TABLE 120 KEY INFORMATION – NOVARTIS AG
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
